-
公开(公告)号:US20240256844A1
公开(公告)日:2024-08-01
申请号:US17782054
申请日:2020-11-11
Applicant: STICHTING KATHOLIEKE UNIVERSITEIT
Inventor: Alexander Ako KHAJETOORIANS , Hilbert Johan KAPPEN
IPC: G06N3/063
CPC classification number: G06N3/063
Abstract: The present invention is in the field of a device comprising an adaptable and addressable neuromorphic structure, a method of operating said neuromorphic structure, a method of acquiring a distribution of states of said neuromorphic structure, and a method of adapting a micro-electronic or nano-electronic device comprising said neuromorphic structure.
-
公开(公告)号:US20230355537A1
公开(公告)日:2023-11-09
申请号:US18076759
申请日:2022-12-07
Inventor: Willem Mulder , Jordi Ochando , Zahi Fayad , Mihai Netea , Leo Joosten
IPC: A61K47/64 , A61K39/39 , C07K14/775 , A61K47/54 , A61K9/51
CPC classification number: A61K9/5123 , A61K39/39 , A61K47/544 , A61K47/64 , C07K14/775 , A61K38/00
Abstract: The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have cancer, by promoting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re- stimulation with one or multiple secondary stimuli.
-
公开(公告)号:US20230333183A1
公开(公告)日:2023-10-19
申请号:US17997636
申请日:2021-05-07
Applicant: Stichting Katholieke Universiteit
Inventor: David Norris
IPC: G01R33/46 , G01R33/48 , G01R33/561
CPC classification number: G01R33/4616 , G01R33/4806 , G01R33/4828 , G01R33/5615
Abstract: The invention provides a method for performing a magnetic resonance measurement of an element in a target region, wherein the element has a magnetic resonance excitation spectrum peak with a linewidth LR, wherein the method comprises a measurement cycle (100) comprising: a magnetization transfer stage (110) comprising providing a plurality of pulses (115) of first radiation to the target region, wherein the plurality of pulses (115) are selected to provide a net pulse having a net pulse angle αN≤1°, and wherein the first radiation comprises a first frequency spectrum peak having a first linewidth LF, wherein the first frequency spectrum peak at least partially overlaps with the magnetic resonance excitation spectrum peak, and wherein LF>5*LR; an excitation stage (130) comprising providing a radio frequency pulse to the target region, wherein the radio frequency pulse excites the element resulting in a transverse magnetization of the element; and a measurement stage (140) comprising detecting a signal from the element, wherein the measurement stage (140) is temporally arranged at an echo time TE after the radio frequency pulse, wherein the echo time TE is smaller than a transverse relaxation time of the element in the target region.
-
公开(公告)号:US11739324B2
公开(公告)日:2023-08-29
申请号:US16451101
申请日:2019-06-25
Applicant: Stichting Katholieke Universiteit
Inventor: Robert Wilhelmus Johanna Collin , Alejandro Garanto Iglesias , Franciscus Peter Maria Cremers
IPC: C12N15/113 , A61K9/00
CPC classification number: C12N15/113 , A61K9/0048 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2320/32
Abstract: The present invention relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Stargardt disease
-
公开(公告)号:US20230022766A1
公开(公告)日:2023-01-26
申请号:US17783548
申请日:2020-12-09
Applicant: NORTHEASTERN UNIVERSITY Center for Research Innovation Northeastern Univ, , Stichting Katholieke Universiteit
Inventor: Sidi A. Bencherif , Jorieke Weiden , Carl Figdor , Martijn Verdoes
IPC: A61K47/69 , A61K47/61 , A61K47/60 , C12N5/0783 , A61K35/17
Abstract: Disclosed are biocompatible cryogels comprising one or more biomolecules, such as antibodies, protein complexes, enzymes, dna and polysaccharides. Also disclosed are methods of making the cryogels.
-
公开(公告)号:US20210123050A1
公开(公告)日:2021-04-29
申请号:US16926040
申请日:2020-07-10
Applicant: STICHTING KATHOLIEKE UNIVERSITEIT
Inventor: Hendrikus Antonius Rudolfus Van Wyk
IPC: C12N15/113
Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Usher syndrome type 2A and/or USH2A-associated non syndromic retina degeneration.
-
87.
公开(公告)号:US20210087583A1
公开(公告)日:2021-03-25
申请号:US16970635
申请日:2019-02-28
Applicant: Stichting Katholieke Universiteit
IPC: C12N15/86 , C07K14/78 , A61K31/7088
Abstract: The present invention relates to the field of medicine. In particular, it relates to therapy for the treatment of Usher syndrome type 2a and USH2A-associated retinitis pigmentosa.
-
公开(公告)号:US10902562B2
公开(公告)日:2021-01-26
申请号:US16300091
申请日:2017-05-15
Applicant: Stichting Katholieke Universiteit
Inventor: Ewoud Joris Smit , Wolfgang Mathias Prokop
Abstract: A system for filtering an input image dataset is disclosed. A plurality of sequences of input signal values, wherein each sequence corresponds to a different attribute, wherein an input signal value is associated with an attribute and a sampling point i. At least one processor 4 is configured to control computing an output signal value corresponding to a sampling point and an attribute. For a particular sampling point i and for each of a plurality of different attributes of the set of attributes, associating a weight to an input signal value based on a similarity between the signal value and for a plurality of the sampling points j excluding the sampling point i. Also the system computes a weighted sum based on the input signal values and weights. The attribute is a location or a frequency.
-
公开(公告)号:US10745699B2
公开(公告)日:2020-08-18
申请号:US16027451
申请日:2018-07-05
Applicant: STICHTING KATHOLIEKE UNIVERSITEIT
Inventor: Hendrikus Antonins Rudolfus Van Wyk
IPC: C12N15/113
Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Usher syndrome type 2A and/or USH2A-associated non syndromic retina degeneration.
-
公开(公告)号:US10071987B2
公开(公告)日:2018-09-11
申请号:US15729267
申请日:2017-10-10
Applicant: Compound Handling B.V. , Stichting Katholieke Universiteit
Inventor: Onno Van Hooij , Jacobus Antonius Schalken , Hendrik Engelbertus Vietor , Dennis Patrick Piet , Petrus Emmanuel Marie Maas , Johann Heinrich Tijhuis , Sirik Deerenberg , Nanda Elisabeth Sprenkels , Siu Ha Tang
IPC: C07D417/04 , C07D417/14 , C07D403/04 , C07D403/14 , A61K31/4155 , A61K31/4184 , A61K31/428 , A61K31/454 , A61K45/06
CPC classification number: C07D403/04 , A61K31/4155 , A61K31/4184 , A61K31/428 , A61K31/454 , A61K45/06 , C07D417/04 , C07D417/14 , H05K999/99
Abstract: A compound having the structure according to formula III wherein: X is NH or S; R1 is H or (1C-4C)alkyl; R2 is (1C-4C)alkyl, phenyl or a monocyclic aromatic ring having one or more N—, O— or S— atoms in the ring, which alkyl, phenyl or aromatic ring is optionally substituted with one or more groups selected from (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, phenyloxy, phenylthio, halogen, or nitro; R3 and R4 are each independently H, (1C-6C)alkyl, (2C-6C) alkenyl, (2C-6C)alkynyl, cyano, (3C-6C)cycloalkyl, phenyl, a monocyclic aromatic ring having one or more N—, O— or S— atoms in the ring, a monocyclic non-aromatic ring having one or more N—, O— or S— atoms in the ring, each optionally substituted with hydroxyl, (1C-4C)alkoxy, phenyl, cycloalkyl, piperidyl, piperazinyl, furyl, thienyl, pirazinyl, pyrrolyl, 2H-pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrrolidonyl, pyrrolinyl, imidazolinyl, imidazolyl, a monocyclic aromatic ring having one or more N—, O— or S— atoms in the ring, whereby each of these optional substituents is optionally further substituted with (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, halogen, nitro or (1C-2C)dioxol forming a ring; or R3 and R4 form together pyrrolyl, imidazolyl, pyrazolyl, pyrrolidinyl, pyrrolinylimidazolidinyl, imidazolinyl, piperidyl, piperazinylmorpholinyl, each optionally substituted with (1C-6C)alkyl, phenyl(1C-4C)alkyl, phenylketo(1C-4C)alkyl; R5 is H, Cl, F, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; R6 is H, (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, nitro or halogen; R7 is H, F, Cl, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; or pharmaceutically acceptable addition salts thereof for use in treatments of carcinoma, in particular, to delay, prevent or reverse metastasis in prostate cancer.
-
-
-
-
-
-
-
-
-